Sign up
Pharma Capital

Concepta PLC making progress after steep learning curve in China

Erik Henau, Concepta PLC’s (LON:CPT) chief executive, believes a more measured approach to its entry into the Chinese market will make progress smoother in future.

Henau says it is been a steep learning curve in China, but the company has made major strides forward.

More staff have been appointed in the country, while new operating procedures have led to ‘huge improvements’ in manufacturing and logistics.

In Europe, the CE process for its urine-based fertility test is progressing and Concepta has started to gently market its MyLotus product in the UK in anticipation of approval in the summer.


View full CPT profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.